Sylvant FDA Approval History
FDA Approved: Yes (First approved April 22, 2014)
Brand name: Sylvant
Generic name: siltuximab
Dosage form: for Injection
Company: Janssen Pharmaceuticals, Inc.
Treatment for: Multicentric Castleman's Disease
Sylvant (siltuximab) is an interleukin-6 (IL-6) antagonist indicated for the treatment of patients with multicentric Castleman’s disease.
Development Timeline for Sylvant
|Apr 23, 2014||FDA Approves Sylvant for Multicentric Castleman’s Disease|
|Sep 3, 2013||Simultaneous Applications Submitted to FDA and EMA for Siltuximab for the Treatment of Multicentric Castleman Disease, a Rare Blood Disorder|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.